Assenagon Asset Management S.A. Sells 136,319 Shares of Edwards Lifesciences Co. (NYSE:EW)

Assenagon Asset Management S.A. trimmed its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 3.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,107,657 shares of the medical research company's stock after selling 136,319 shares during the period. Edwards Lifesciences comprises about 0.5% of Assenagon Asset Management S.A.'s holdings, making the stock its 26th largest position. Assenagon Asset Management S.A. owned approximately 0.70% of Edwards Lifesciences worth $297,723,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in EW. Trueblood Wealth Management LLC boosted its holdings in Edwards Lifesciences by 34.0% during the 1st quarter. Trueblood Wealth Management LLC now owns 4,949 shares of the medical research company's stock worth $359,000 after acquiring an additional 1,256 shares during the last quarter. Terra Alpha Investments LLC boosted its holdings in Edwards Lifesciences by 4.7% during the 1st quarter. Terra Alpha Investments LLC now owns 22,600 shares of the medical research company's stock worth $1,638,000 after acquiring an additional 1,020 shares during the last quarter. Manitou Investment Management Ltd. boosted its holdings in Edwards Lifesciences by 5.7% during the 1st quarter. Manitou Investment Management Ltd. now owns 189,656 shares of the medical research company's stock worth $13,746,000 after acquiring an additional 10,205 shares during the last quarter. Wealthcare Advisory Partners LLC boosted its holdings in Edwards Lifesciences by 5.8% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 7,769 shares of the medical research company's stock worth $563,000 after acquiring an additional 429 shares during the last quarter. Finally, Pallas Capital Advisors LLC purchased a new position in Edwards Lifesciences during the 1st quarter worth $222,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Price Performance

EW traded down $0.77 on Friday, reaching $75.12. The company had a trading volume of 2,635,771 shares, compared to its average volume of 5,226,474. The business has a 50 day simple moving average of $74.54 and a 200 day simple moving average of $72.92. The company has a market cap of $44.06 billion, a price-to-earnings ratio of 10.78, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same period last year, the firm posted $0.66 earnings per share. The business's revenue was up 6.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on EW. Robert W. Baird boosted their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a report on Thursday, April 24th. Truist Financial cut their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Canaccord Genuity Group boosted their price target on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a report on Friday, April 25th. Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Finally, Piper Sandler boosted their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a report on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $80.20.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the company's stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total value of $797,287.50. Following the sale, the chief financial officer now directly owns 30,387 shares of the company's stock, valued at $2,153,526.69. This represents a 27.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bernard J. Zovighian sold 5,980 shares of the company's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $74.91, for a total transaction of $447,961.80. Following the completion of the transaction, the chief executive officer now owns 58,284 shares in the company, valued at approximately $4,366,054.44. The trade was a 9.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 42,948 shares of company stock worth $3,122,845 over the last quarter. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.